Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tanuja Chitnis, M.D.

Co-Author

This page shows the publications co-authored by Tanuja Chitnis and Samia Khoury.
Connection Strength

4.803
  1. Sex influences in autoimmune disease. Clin Immunol. 2013 Nov; 149(2):169.
    View in: PubMed
    Score: 0.580
  2. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol. 2007 May; 170(5):1695-712.
    View in: PubMed
    Score: 0.376
  3. Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Mar; 5(1):11-26.
    View in: PubMed
    Score: 0.323
  4. Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol. 2004 Apr 01; 172(7):4260-5.
    View in: PubMed
    Score: 0.304
  5. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol. 2003 Nov; 112(5):837-49; quiz 850.
    View in: PubMed
    Score: 0.295
  6. 20. Immunologic neuromuscular disorders. J Allergy Clin Immunol. 2003 Feb; 111(2 Suppl):S659-68.
    View in: PubMed
    Score: 0.280
  7. Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res. 2003; 28(3):223-39.
    View in: PubMed
    Score: 0.278
  8. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Sep; 108(5):739-47.
    View in: PubMed
    Score: 0.254
  9. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Mar; 107(5):575-83.
    View in: PubMed
    Score: 0.245
  10. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
    View in: PubMed
    Score: 0.148
  11. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
    View in: PubMed
    Score: 0.146
  12. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.144
  13. Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol. 2013 Mar; 146(3):176-84.
    View in: PubMed
    Score: 0.139
  14. Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt. 2011 Feb; 16(2):021109.
    View in: PubMed
    Score: 0.122
  15. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci. 2010 Feb 10; 30(6):2025-38.
    View in: PubMed
    Score: 0.114
  16. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol. 2008 Aug; 173(2):411-22.
    View in: PubMed
    Score: 0.102
  17. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006 Mar 15; 176(6):3480-9.
    View in: PubMed
    Score: 0.087
  18. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol. 2006 Jan; 63(1):25-33.
    View in: PubMed
    Score: 0.086
  19. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005 May; 106(2):163-77.
    View in: PubMed
    Score: 0.080
  20. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest. 2003 Oct; 112(7):1037-48.
    View in: PubMed
    Score: 0.073
  21. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003 Jul 07; 198(1):71-8.
    View in: PubMed
    Score: 0.072
  22. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
    View in: PubMed
    Score: 0.058
  23. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.051
  24. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
    View in: PubMed
    Score: 0.048
  25. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  26. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
    View in: PubMed
    Score: 0.036
  27. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
    View in: PubMed
    Score: 0.033
  28. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.032
  29. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.031
  30. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
    View in: PubMed
    Score: 0.030
  31. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  32. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.030
  33. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 Sep 15; 183(6):4067-76.
    View in: PubMed
    Score: 0.028
  34. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.027
  35. A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2009 Jan 03; 206(1-2):76-85.
    View in: PubMed
    Score: 0.026
  36. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci. 2006 Sep 20; 26(38):9794-804.
    View in: PubMed
    Score: 0.023
  37. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003 Jul 07; 198(1):63-9.
    View in: PubMed
    Score: 0.018
  38. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol. 2003 Mar; 136(1-2):140-8.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.